| __timestamp | BeiGene, Ltd. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6930000 | 15746000 |
| Thursday, January 1, 2015 | 7311000 | 13392000 |
| Friday, January 1, 2016 | 20097000 | 9290000 |
| Sunday, January 1, 2017 | 62602000 | 7672000 |
| Monday, January 1, 2018 | 195385000 | 15293000 |
| Tuesday, January 1, 2019 | 388249000 | 22648000 |
| Wednesday, January 1, 2020 | 600176000 | 21864000 |
| Friday, January 1, 2021 | 990123000 | 37318000 |
| Saturday, January 1, 2022 | 1277852000 | 48130000 |
| Sunday, January 1, 2023 | 1504501000 | 108146000 |
Cracking the code
In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of BeiGene, Ltd. and Madrigal Pharmaceuticals, Inc. from 2014 to 2023. Over this period, BeiGene's SG&A expenses skyrocketed by over 21,000%, reflecting its aggressive expansion and investment in global operations. In contrast, Madrigal Pharmaceuticals saw a more modest increase of around 587%, indicating a more conservative growth strategy.
By 2023, BeiGene's expenses reached approximately 1.5 billion, dwarfing Madrigal's 108 million. This stark difference highlights the varying strategic approaches of these two companies in the biotech sector. As investors and industry watchers analyze these trends, the data offers insights into how each company allocates resources to drive innovation and market presence.
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and BeiGene, Ltd.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
BeiGene, Ltd. and Exelixis, Inc.: SG&A Spending Patterns Compared
BeiGene, Ltd. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xenon Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xencor, Inc.
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
Operational Costs Compared: SG&A Analysis of Madrigal Pharmaceuticals, Inc. and Xencor, Inc.